arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Black Diamond Therapeutics, Inc.

BDTX
$1.65 ▼ -0.25 (-12.93%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
32 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Black Diamond Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $94.7M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -9.9% ↘
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-9.04M
— 0.0% —
FCF / Share Free cash flow per share
$-0.14
↑ +22.3% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
87
Returns
86
Cash Quality ↑
76

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 32 quarters